"Ambrano", a new heavyweight drug of Haizheng pharmaceutical, is expected to be approved for market within this year
-
Last Update: 2014-09-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Ambroxol is the first McAb drug in Haizheng pharmaceutical industry, which completed phase III clinical treatment in 2011 and declared for production on July 12, 2013 In April this year, the company submitted supplementary information to the drug regulatory bureau, and entered the status of waiting for on-site inspection at the end of July According to the public information, ambroxol's original research drug is Pfizer's enri (trade name), which is the world's first all-human soluble tumor necrosis factor antagonist for the treatment of rheumatoid arthritis and ankylosing spondylitis Haizheng pharmaceutical is mainly engaged in antibiotics and anti-tumor drug APIs, and is planning to transform from a single API to a high-end preparation Gene drugs and macromolecular drugs are an important part of the company's transformation Previously, an insider of the company told the big smart news agency that in addition to ambano, the company has a echelon of reserve products in this field.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
